Search Results - "E. Yu. Solovyeva"

The mechanisms for activation of a vascular platelet component of hemostasis in the stroke recovery period and the ways of their correction by Tyutyumova, E. A., Solovyeva, E. Yu, Karneev, A. N., Dzhutova, E. D.

“…Objective: to assess changes in the vascular platelet component of hemostasis in patients in different recovery periods of ischemic stroke (IS).Patients and…”
Get full text

Studies of the Membrane-Protecting Potential of the Combination of 2-Ethyl-6-Methyl-Hydroxypyridine Succinate and Citicoline by Solovyeva, E. Yu, Karneev, A. N., Chekanov, A. V., Baranova, O. A., Shchelkonogov, V. A., Sinebryukhova, A. M., Farakhova, K. I., Sorokoumova, G. M.

“…Objectives. To assess changes in the phospholipid composition of blood plasma in patients with chronic cerebrovascular disease using the neuroprotectors…”
Get full text

Therapy for back pain syndrome by E Yu Solovyeva

“…There is evidence that nonsteroidal anti-inflammatory drugs (NSAIDs) may be used in combination with B group vitamins. A number of independent trials…”
Get full text

The study of the membrane-protective potential of the combination of 2-ethyl-6-methyl-3-hydroxypyridine-succinate and citicoline by Solovyeva, E Yu, Karneev, A N, Chekanov, A V, Baranova, O A, Shchelkonogov, V A, Sinebryukhova, A M, Farakhova, K I, Sorokoumova, G M

“…To assess the changes in the composition of plasma phospholipids in patients with chronic cerebrovascular disease treated with neuroprotectors…”
Get more information

Complex application 2-ethyl-6-methyl-3-hydroxypyridine-succinate and vinpocetine in cerebrovascular disorder. by Solovyeva, E Yu, Karneev, A N, Chekanov, A V, Baranova, O A, Choi, I V

“…Developing brain ischemia due to cerebral vascularization leads to disruption of brain metabolism. Chronic cerebral hypoperfusion leads to irreversible brain…”
Get more information

The individual and combined antioxidant effects of citicoline and ethylmethylhydroxypyridini succinas by Solovyeva, E Yu, Karneev, A N, Chekanov, A V, Baranova, O A

“…To study the antioxidant status of patients with chronic cerebral ischemia (CCI) during the individual treatment with…”
Get more information

Treatment for mixed cognitive impairments and emotional disorders in young and middle-aged patients by Parfenov, V. A., Solovyeva, E. Yu, Antonenko, L. M., Lokshina, A. B., Gorskaya, T.

“…Objective: to evaluate the efficacy of Tanakan® (EGB761®) used in young and middle-aged patients with mixed cognitive impairments (CI) and emotional…”
Get full text

ESCADRA: a randomised study. Part I: lipid-lowering effectiveness, safety and tolerability of ezetimibe, initial doses of original statins, and the combination of ezetimibe with initial doses of statins in patients with coronary heart disease and hyperlipidemia by M. Yu. Zubareva, T. A. Rozhkova, E. Yu. Solovyeva, A. V. Susekov

“…Aim. To study the lipid-lowering effectiveness, as well as the effects on inflammatory markers and vascular wall function, of ezetimibe as monotherapy and in…”
Get full text

Double cholesterol inhibition — a new approach to effective control of hyperlipidemia and atherosclerosis by A. V. Susekov, N. B. Gornyakova, M. Yu. Zubareva, T. A. Rozhkova, E. Yu. Solovyeva

“…The increased level of low-density lipoprotein cholesterol (LDL-CH) is one of the risk factors (RFs) of coronary heart disease and atherosclerosis. Statins,…”
Get full text

Pathogenetic and therapeutic aspects of cardioembolic stroke by Romanenko, A V, Solovyeva, E Yu

“…Cardioembolic stroke (CS) is the one of the most severe and requiring dynamic monitoring among the all subtypes of ischemic stroke. Patients with CS require…”
Get more information

Possibilities of personalized pharmacotherapy and medical rehabilitation of patients with long COVID from the perspective of clinical metabolomics by Kukes, I. V., Lim, V. G., Ivantsov, K. A., Solovyeva, E. Yu, Sokolova, L. P., Gilmutdinova, I. R., Glagovskiy, P. B., Ptitsyn, M. S.

“…Introduction . The material presents the results of the study of the effectiveness of the drug Ethylmethylhydroxypyridine malate in  patients with long COVID,…”
Get full text

Coronary heart disease development in heterozygotic form of familial hypercholesterolemia by P. P. Malyshev, T. A. Rozhkova, E. Yu. Solovyeva, A. N. Meshkov, V. V. Kukharchuk

“…Aim. To assess coronary heart disease (CHD) and its risk factors (RF) prevalence, as well as their interaction in patients with heterozygotic form of familial…”
Get full text

Phenotypical features of a heterozygous form of familial hypercholesterolemia by Malyshev, P P, Rozhkova, T A, Solov'eva, E Iu, Meshkov, A N, Kaminnaia, V I, Kukharchuk, V V

“…To conduct a quantitative and qualitative analysis of phenotypical manifestations in patients with a heterozygous form of familial hypercholesterolemia (FHC)…”
Get more information

Simvastatin in management of patients with primary hypercholesterolemia: tolerability and efficacy of daily doses 10-80 mg by Susekov, A V, Solov'eva, E Iu, Rozhkova, T A, Kotova, L A, Akhmedova, Z A, Kukharchuk, V V

“…To analyze retrospectively data on lipid lowering efficacy, tolerability and safety of different doses of simvastatin in patients with primary hyperlipidemia…”
Get more information